S1487 Inflammatory Bowel Disease-Associated Peripheral Spondyloarthritis (IBD-pSpA) Negatively Influences Health Related Quality of Life Across Multiple Patient Reported Outcomes—Results From the CHASE Cohort

Introduction: Inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (IBD-pSpA) is common but not well studied, with limited data regarding impact on health-related quality of life (HRQoL). The aim of this study was to evaluate whether IBD-pSpA negatively impacts HRQoL via use of previously validated patient reported outcome measures (PROs). Methods: We prospectively recruited patients with IBD-pSpA, defined by previously established consensus criteria via the Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal Manifestations (CHASE-EIM), from 6 sites across the United States along with controls with IBD but no prior history of joint disease. All patients completed the Inflammatory Bowel Disease Questionnaire (IBDQ), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F). Analyses were performed using R software and a significance level of 0.05 was assumed. Results: We recruited 235 patients (134 with IBD-pSpA and 101 controls with IBD but no history of joint disease). When compared with controls, patients with IBD-pSpA were older (median 43.2 [32.3; 53.8] vs 31.1 years [25.0; 39.9], P < 0.001), more often women (61.2% vs 46.0%, P = 0.029), had longer disease duration (median 14.5 [7.50; 26.1] vs 9.0 years [3.65;1 5.4], P < 0.001), and were more likely to have Crohn’s disease (70.1% vs 54.0%, P = 0.016). There were no statistically significant differences between groups with respect to IBD disease activity in the bowel as per global physician impression, endoscopy, or imaging, though patients with IBD-pSpA were statistically more likely to have an elevated CRP (30.4% vs 8.6%, P = 0.024). They were also more likely to be on medications commonly used to treat IBD-pSpA (sulfasalazine and methotrexate). Patients with IBD-pSpA had statistically worsened WPAI scores across all domains. They also had lower median IBDQ scores (158 [127; 184] vs 185 [164; 204], P < 0.001) and lower FACIT-F scores (29 [19.0; 37.0] vs 42 [34.0; 47.0]). Conclusion: The presence of IBD-pSpA is significantly associated with worsened HRQoL across multiple PRO domains, highlighting the need for further research to improve therapeutic management of this underserved patient population.